SC
GILD icon

Scholtz & Company’s Gilead Sciences GILD Stock Holding History

Scholtz & Company’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-26,950
Closed -$2.87M – 57
2014
Q3 		$2.87M Sell
26,950
-21,740
-45% -$2.13M 2.83% 12
2014
Q2 		$4.04M Buy
48,690
+4,375
+10% +$341K 3.82% 3
2014
Q1 		$3.14M Buy
+44,315
New +$3.48M 3.36% 7

Other funds holding GILD

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Scholtz & Company's GILD Position: Q4 2014 in Review

Scholtz & Company sold out of Gilead Sciences (GILD) in Q4 2014, closing a stake of 26,950 shares — an estimated $2.87M sold.

Scholtz & Company first reported a position in GILD in Q1 2014 and held it in 3 quarters. The position peaked at $4.04M in Q2 2014. 1,438 funds tracked by Wall St. Rank hold GILD as of Q4 2014.

  • Scholtz & Company reported no remaining Gilead Sciences position as of Q4 2014 after selling out during the quarter.
  • Scholtz & Company sold 26,950 Gilead Sciences shares in Q4 2014, an estimated $2.87M.
  • Scholtz & Company first reported a position in Gilead Sciences in Q1 2014 and held it in 3 quarters.
  • Scholtz & Company's Gilead Sciences position peaked at $4.04M in Q2 2014.
  • 1,438 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2014.

Based on Scholtz & Company's 13F filing for Q4 2014, filed 13 Feb 2015.